How the Year’s Top Licensing and M&A Transactions Are Changing the Industry Landscape
As external innovation continues to be a critical part of portfolio strategy for the biggest BioPharma players, it drives the deals activity as companies race to license and acquire the assets that will give them market segment dominance. All indications are that 2018 will another mega-dealmaking year as big dollars have flowed forth for licensing and M&A deals in the first half of the year. Using Cortellis tools, our experts delve into these partnerships and M&As to provide attendees with valuable market insights: